Indeglitazar

Indeglitazar is a pharmaceutical drug that belongs to the class of thiazolidinediones, which are used primarily for the treatment of diabetes mellitus type 2. It is an insulin sensitizer that works by binding to the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ and PPARα, to regulate the transcription of genes involved in glucose and lipid metabolism.

Mechanism of Action[edit | edit source]

Indeglitazar acts as a dual PPAR agonist, meaning it activates both PPARγ and PPARα. PPARγ activation improves insulin sensitivity and decreases blood glucose levels, while PPARα activation reduces triglyceride levels in the blood. This dual action makes indeglitazar a potentially effective treatment for type 2 diabetes and its associated dyslipidemia.

Clinical Trials[edit | edit source]

Indeglitazar has undergone clinical trials to assess its safety and efficacy in treating type 2 diabetes. In a phase II trial, indeglitazar demonstrated significant reductions in HbA1c levels, a marker of long-term blood glucose control, compared to placebo. However, further development of the drug was halted due to concerns about its safety profile.

Side Effects[edit | edit source]

Like other thiazolidinediones, indeglitazar has been associated with several side effects. These include weight gain, fluid retention, and an increased risk of heart failure. It may also increase the risk of bone fractures and bladder cancer, although these risks are not fully understood and require further study.